As spotted by Android Authority, Google has quietly added the bookmark bar to Chrome for Android. It's the same bookmark bar ...
Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to improve ...
A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...
The Kimwolf botnet, an Android variant of the Aisuru malware, has grown to more than two million hosts, most of them infected ...
Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...
Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 trial designed to evaluate its anti-TIGIT therapy domvanalimab in gastric and ...
Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...
RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they’ll focus now on Casdatifan (AB521), ...
Arcus BiosciencesRCUS stock plunged Friday, reversing a nearly 300% gain over the past eight months, after its Gilead SciencesGILD-partnered cancer regimen failed its Phase 3 test. The duo tested a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback